Recent studies have shown an association between trinucleotide repeat expansions (TREs) and adult-onset schizophrenia (AOS). Childhood-onset schizophrenia (COS) is a severe variant of schizophrenia with onset of symptoms before age 12 years. We have used the repeat expansion detection (RED) method to investigate the occurrence of repeat expansions in a group of well-characterized COS patients as well as a set of clinically related childhood-onset psychosis cases labeled 'multidimensionally impaired' (MDI). The difference observed in the CAG/CTG RED product distribution between normal (n = 44) and COS (n = 36) samples was only marginally significant (P = 0.036). However, male COS samples (n = 20) had a significantly different RED product distribution compared to male controls (n = 25, P = 0.002) with longer RED products in COS. No such difference was seen in females (n cont = 19; n COS = 16; P = 0.236). The difference remained significant between male COS (n = 12) and male controls (n = 24) when only Caucasian samples were used (P = 0.003). Similarly, the RED product distribution in male MDI samples (n = 18) was significantly different compared to male controls (P = 0.018). Some of the detected TREs in all three populations (COS, MDI and control) correlated with expanded alleles found at the CTG18.1 locus on chromosome 18. In conclusion, we have found an association between TREs and COS. This association is specifically significant in the male population. Thus, the occurrence of an expanded trinucleotide repeat may contribute to the genetic risk of COS, possibly in combination with other factors.
Introduction
The general population has a 1% lifetime risk for schizophrenia. Although many possible causes for the disorder have been suggested, the results of family, twin and adoption studies have indicated a genetic component to the illness. 1 However, extensive genome scans, multiplex studies of pedigrees and attempts at association studies have as yet yielded no replicable evidence of candidate genes demonstrating a predisposition towards schizophrenia.
Childhood-onset schizophrenia (COS) has long been recognized as a rare and usually severe variant of schizophrenia. COS is a multi-faceted psychotic disorder and has been described previously by DeSanctis, 2 Blueler 3 and Kraeplin. 4 By definition, patients must meet adult onset schizophrenia (AOS) criteria with Correspondence: M Schalling, Neurogenetics Unit, Center for Molecular Medicine, L8:00, Karolinska Hospital, 17176 Stockholm, Sweden Received 19 August 1997; revised 7 January 1998 and 4 March 1998; accepted 4 March 1998 onset of psychotic symptoms before age 12.
5-7 COS has been associated with greater disease severity than AOS and may also be associated with a greater heritability. 7 The disorder has a treated prevalence of 1/50th that of AOS. 8, 9 COS has an insidious onset with pre-existing personality abnormalities, premorbid social impairment and symptoms including thought blocking, delusions and hallucinations (mostly auditory). While a high male to female ratio has been reported in some series, 10 equal male and female ratios are seen in others. 5 It is generally accepted that COS is an early onset variant of the adult disorder with similarities seen in brain abnormalities, smooth pursuit eye movements, autonomic physiology, and clinical symptomology. 7, 11, 12 A poor response to neuroleptics has also been associated with this early onset disorder. [13] [14] [15] [16] An earlier onset has been found to be related to a poor outcome in numerous studies 17 and, on the basis of multiple studies of age at onset, DeLisi 18 concludes that age of onset is the 'single most important characteristic of schizophrenia that could yield clues to its origin'.
Expanding trinucleotide repeats have been identified as the mutational mechanism in a number of neuropsy-chiatric disorders. These pathologically expanding trinucleotides are heritable DNA sequences which, in a disease state, become markedly unstable and may expand slightly or by the thousands within a single generation. These changes may influence gene expression, message stability and protein structure. 19 Such trinucleotide repeat expansions (TREs) have yielded the molecular mechanisms behind a number of disorders including several spinocerebellar ataxias, Huntington's disease, fragile X syndrome, and myotonic dystrophy. 20 The common feature of these disorders is that they display anticipation wherein the severity of the disorder increases and the age of onset decreases in successive generations. Anticipation correlates with an increased expansion size in the DNA sequence and can be seen in most disorders with this mutational mechanism. Recent studies have demonstrated the presence of anticipation within multiplex families presenting with AOS. [21] [22] [23] [24] [25] Investigations of unstable repeat sequences in AOS have identified an association between CAG/CTG TREs and AOS patients suggesting a possible role for repeat expansions in the pathogenesis. [26] [27] [28] [29] In most trinucleotide disorders, the largest TRE sizes are found in juvenile cases of the normally adult-onset disorder. Assuming that COS is an earlier onset variant of AOS, we investigated the occurrence of repeat expansions using the RED method 30 on DNA samples from a group of well-characterized childhood-onset schizophrenia patients collected at the NIMH. All patients were non-responders to typical neuroleptics and were clinically similar to adult-onset cases with very early onset and poor outcome. Additionally, a set of childhood-onset psychosis cases not meeting all of the DSM-III-R criteria for COS were collected and investigated for repeat expansions. These individuals demonstrated symptoms clinically similar to those seen in COS and were provisionally labeled 'multidimensionally impaired' (MDI). These subjects were primarily male with onset of psychiatric difficulties at earlier ages than the COS group.
Materials and methods

Patient material
COS and MDI subjects Male and female patients with COS, aged 6-18 years, were recruited nationally through Announcements to the American Academy of Child and Adolescent Psychiatry and the National Alliance for the Mentally Ill seeking referrals of children meeting DSM-III-R criteria for schizophrenia with onset of psychotic symptoms at or before age 12 years. Mental retardation and neurological disorders were exclusionary. Over 600 charts were reviewed and, after examination of 168 patients and families, 36 patients (20 males, 16 females) received the diagnosis of childhood-onset schizophrenia and 22 patients (18 males, four females) received the diagnosis of multi-dimensionally impaired (MDI). Since the children were participating in a clozapine treatment trial, they were nonresponders to previous neuroleptic agents. 31 Detailed descriptions of the interviewing process and selection criteria are reviewed elsewhere. 32, 33 Blood was taken following informed parental consent and cell lines were established.
The family history for psychiatric illness in COS subjects included three individuals (parental generation) with schizotypal/avoidant behavior; three individuals (two parents, one sibling) with schizotypal behavior; two individuals (parents) with paranoid behavior; and three individuals (two parents, one sibling) with avoidant behavior. In the MDI group, there was one individual (parent) with schizotypal/avoidant behavior and one individual (parent) with paranoid behavior.
Control subjects Controls were recruited from the Washington, DC area. Controls were physically healthy including all first-degree relatives. All control subjects underwent structured psychiatric interviews and a short form WISC IQ test as well as behavioral rating scales completed by parents and teachers as described elsewhere. 34 Any subject with previous speech or language therapy or any form of remedial tutoring was excluded. Additionally, psychiatric disorders in parents or siblings and major disorders (schizophrenia or bipolar disorders) in second degree relatives were also exclusionary. Thus, approximately 80% of the population was eliminated. From the selected sub-population, blood was taken following informed parental consent and cell lines were established. From this group, age-and sex-matched controls were selected (25 males, 19 females).
Mean age for subjects The mean age for COS samples was 14.9 years with an age range of 9.2-21.9 years. Male COS samples had a mean age of 15.3 years and females 14.4 years. The mean age for MDI subjects was 12.7 years with an age range of 6.8-18.0 years. Mean age for males was 12.6 years and for females 13.4 years. The control group mean age was 13.3 years with a range of 5.1-23.3 years. The mean age for males was 13.3 years and for females was 13.3 years.
Ethnic composition
The ethnic compositions of the populations were as follows: COS males-six AfroAmerican, one Indian, one Iranian/Caucasian, and 12 Caucasian; COS females-six Afro-American, three Hispanic, one Philipino, one Israeli/Caucasian, five Caucasian; MDI males-one Hispanic, 17 Caucasian; MDI females-one Hispanic, three Caucasian; control males-23 Afro-American, one Hispanic/Caucasian, 21 Caucasian; control females-four Afro-American, one Hispanic, one Hispanic/Caucasian, one Oriental, 12 Caucasian. In several instances, individuals had mixed ethnic parentage and were considered separate from each ethnic classification. The Caucasian subgroup is of mixed European descent as most studies of RED and repeat product sizes show little variation within continentally-clustered groups.
35-37
RED analysis
The RED reaction is as previously described 38,39 using a (CTG) 10 oligonucleotide which produces a repeat size representation at 30 nucleotide intervals. Briefly, amplified products were separated on a 6% denaturing polyacrylamide gel, blotted to Hybond-N™ membrane, UV-crosslinked, and hybridized with a 3Ј-32 P-labeled (CAG) 10 oligonucleotide. The membrane was exposed to film for 24-36 h and the largest ligation products for each sample were identified. Replicate analyses confirmed the repeat length for each individual. RED product size distributions were analyzed statistically.
PCR screening
Primer sequences 1a and 1b for the CTG18.1 locus were as originally reported. 40 PCR reactions containing 40-100 ng genomic DNA, 1.5 M of each primer, 5% DMSO, 0.2 mM dNTPs, 50 mM KCl, 1.5 mM MgCl 2 , 10 mM Tris pH 8.3 and 0.1% gelatin in 20 l, were amplified by 5 min primary denaturation at 95°C followed by 15 cycles of 91°C for 50 s, 56°C for 100 s and 72°c for 60 s and 15 cycles of 94°C for 50 s, 56°C for 100 s, 72°C for 60 s and a final extension of 6 min at 72°C. PCR products were heat denatured in 50% formamide for 5 min before separation on a 6% denaturing polyacrylamide/6 M urea gel. DNA from the polyacrylamide gel was transferred by capillary blotting onto Hybond-N™ membrane for 2 h. Following UV immobilization, the membranes were hybridized to a (CAG) 10 oligonucleotide and autoradiographed for 0.5-12 h.
Statistical analysis
All statistical analyses were performed using a Wilcoxon-Mann-Whitney U test for independent samples on nonparametric measurements with the correction for ties. This test was used to compare the total distribution of CAG/CTG RED products. Because the hypothesis tested specified a direction of effect, onetailed P-values were used.
Results
Thirty-six childhood-onset schizophrenic and 44 ageand sex-matched control DNA samples were examined for the presence of TREs using the repeat expansion detection (RED) 30 method. An initial screening of several repeat motifs (excluding ATT/AAT and CCG/CGG) showed an increased expansion frequency for the CAG/CTG motif but not for other motifs (data not shown). Thus additional samples were screened using a (CTG) 10 oligonucleotide (Figure 1 ). The frequency of large CAG/CTG RED products (Ն180 nucleotides (nts)) found in controls was 29.5% (n = 44) which correlates well with previous observations. 30, 41 In COS samples (n = 36), 42% of DNAs tested exhibited RED products Ն180 nts. The difference in the RED product distribution observed between normal and COS samples was significant (P = 0.036). However, male COS samples (n = 20) as compared to male controls (n = 25) exhibited a more significant difference in the distribution of CAG/CTG RED products (P = 0.002) with a RED product frequency Ն180 nts of 50% in COS males and 12% in control males (Figure 2) . No difference in RED product distribution was observed between affected (n = 16) and control females (n = 19, P = 0.236). Additionally, the average RED product size in COS males was 176 nts vs a control male average of 131 nts (Table 1) .
Concerns regarding the importance of ethnicity in RED product distribution 37 led us to compare matched ethnic groups. For this analysis, we excluded four control males, seven control females, eight COS males and 11 COS females of non-Caucasian origin. A marked difference in the frequency of Ն180 nts RED products was seen between the two Caucasian subgroups (53% COS (n = 17) vs 30% controls (n = 33)) demonstrating a significant difference in the total RED product distribution (P = 0.005). However, we observed no excess accumulation of Ն180 nts RED products in the nonCaucasian COS samples (male + female, n = 19) vs controls (n = 11) (32% vs 27%, respectively). The male Caucasian subgroups showed a highly significant difference in the RED product distribution (P = 0.0017) with a Ն180 nts RED product frequency of 58% in COS males (n = 12) and 14% in control males (n = 21). An average RED product size of 185 nts in COS males vs 132 nts in control males was observed. The low repeat frequency in the control males as compared to previous studies 30, 37, 41 led us to compare the Caucasian male COS group (n = 12) also to a separate larger control group 41 of Swedish adult males (n = 90) constituting a more conservative comparison. Even in this case, there Determined as compared to controls designated (1) through (5).
was a significant difference in RED product distribution (P = 0.005). RED product analysis was also performed on the DNA from 22 MDI patients. The same control population was used for both the COS and MDI samples. The RED product frequency Ն180 nts in the MDI population (n = 22) was 41%. The difference in the RED product distribution in the MDI population (male + female) vs controls (n = 44) was nonsignificant (P = 0.156); however, the male MDI subgroup (n = 18), showed a significant difference as compared to controls (n = 24, P = 0.018). The average RED product size for the males was 170 nts. The females could not be evaluated due to small sample size (n = 4). A 32% increased incidence of Ն180 nts RED products was seen in the male MDI population as compared to controls (44% vs 12%) and, in an ethnically matched population of MDI Caucasian males (n = 17) compared to Caucasian controls (n = 21), a significant difference in distribution was seen (P = 0.028). In comparison to the Swedish adult male group 41 however, the difference was nonsignificant (P = 0.121) (see Table 1 ).
Given the phenotypic similarities between COS and MDI, we also analyzed the two groups as a single population. The RED product frequency Ն180 nts in this combined population was 43% (n = 56) with a 47% frequency in the combined male population (n = 38). The difference in the RED product distribution was significant as compared to controls in the combined population (P = 0.042) and in both the male group (P = 0.005) and in the male Caucasian subgroup (n = 30, P = 0.004). The average RED product size for the com-bined group was 166 nts, with 173 nts in the males (COS + MDI) and 178 nts in the male Caucasian subgroup.
Since we were investigating the occurrence of novel trinucleotide expansions, we also excluded known pathological repeat expansions using PCR or Southern blot analysis. We screened an initial set of male patients for the FRAXA expansion as well as for Huntington's disease, dentatorubral and pallidoluysian atrophy (DRPLA), spinocerebellar ataxia type I (SCA1), Machado-Joseph disease (MJD/SCA3), and spinobulbar muscular atrophy (SBMA). All analyses were negative (data not shown) indicating our COS phenotypes did not arise from either a CCG/CGG or CAG/CTG repeat expansion in previously identified loci. Karyotype analyses performed on these patients demonstrated chromosomal abnormalities in some COS and MDI patients. These included a 1 : 7 translocation in one COS male and other abnormalities in two COS and three MDI males. 7 In an attempt to identify the observed TREs, we screened many polymorphic CAG/CTG loci using PCR. To date, expansions have been found in two loci containing unstable polymorphic CAG/CTG repeats mapping to chromosome 18q21.1 (CTG18.1) 40 and to chromosome 17q (DIR1/ERDA1). 42, 43 CTG18.1 shows 84% heterozygosity in control individuals. 40 PCR analysis identified 16 individuals with CTG18.1 expansions similar in size to those seen by RED analysis. These samples included three female COS, four male COS, four male MDI, and one male control and four female controls. The difference in RED product distribution between male COS (n = 16) and male controls (n = 24) remained significant (P = 0.012) even after exclusion of all individuals with a CTG18.1 expansion. In the MDI sample, CTG18.1 expansions correlating with RED product sizes were found in four males. One sample showed evidence of two expansions by RED analysis (210 nts and 480 nts expansions) and was excluded from this analysis. No difference in RED product distribution was observed between the control population and the MDI males following exclusion of all individuals with a CTG18.1 expansion (P = 0.109). However, we observed a weak but significant association between the CTG18.1 expansion and the combined male COS/MDI population using chi-squared analysis (P Ͻ 0.05).
The DIR1/ERDA1 42,43 locus was published after completion of this study. This is a highly polymorphic locus and is found as an expanded allele in approximately 30% of the Caucasian population. 44 We have analyzed this repeat locus in a separate study. 45 
Discussion
Recent brain MRI studies of patients with COS have identified brain anatomic abnormalities which are consistent with those reported in adult schizophrenia populations 12 indicating an overall continuity with the childhood disorder. The type of onset differentiates AOS and COS with a more insidious and less acute onset being characteristic of the childhood variant. However, because an early and insidious onset represents a negative prognostic factor, this is consistent with COS representing a more severe form of the disorder. In fact, COS is considered to be symptomatologically equivalent to AOS poor outcome individuals. Based on these observations, it is possible that AOS and COS are two aspects of a single disorder.
It is not known if MDI and COS are etiologically heterogeneous or a single disorder with variable expression due to moderating factors (ie pleiotropy). Similarities between the two disorders exist in both brain morphology and the proportion of families with additional members affected by schizotypal or paranoid personality disorders. A similar frequency of expanded CAG/CTG alleles in the two male groups (50% in COS, 44% in MDI) and a similar average expansion size (176 nts in COS and 170 nts in MDI) hint that these disorders might be two subtypes of a single disorder. Due to a smaller average RED size in our control male population than in previously reported controls, we compared our affecteds to a second male control population. 41 In this analysis, a significant difference between the COS male Caucasian population and the alternate controls is seen while in the MDI male Caucasian population no significant difference is apparent. Thus, the initial significance seen in the male MDIs appears to be due mainly to the small male control repeat size while, in the COS samples, it is more likely related to an increase in the number of expanded repeats. Therefore, whether this is a true variation in the MDI population or the result of sampling variability in the male controls needs to be further investigated.
One of the more surprising findings of this study was the marked difference in the average size of expansions between male and female samples. In the controls, average RED product sizes in females were significantly larger than those found in males. This variation is probably due to chance as only one previously published study has shown a difference between male and female RED sizes 26 and this variation was the inverse of ours (ie males 38% expanded; females 16% expanded). To compensate for this possibility, we have compared our samples to a previously defined adult control group. 41 Unfortunately, no other published RED studies of childhood samples could be found for comparison. Additionally, no other childhood control samples were available for analysis prior to publication. We are currently collecting additional samples to determine if this is a true finding or a sampling artifact. Interestingly, in the COS sample, there was a large excess of expanded repeats in the COS males as compared to the COS females. This excess of expansions in the male sample accounts for the difference seen in the combined (male + female) sample. Whether the sex difference seen in the RED product distribution is real or just a chance finding remains to be seen. However, no previous examples of autosomal unstable DNA diseases with different sized expansions between male and female affecteds have been reported. Replicate studies in separate and larger populations of COS samples are therefore required to confirm both the association of an increased repeat size and a sex-associated difference.
Although there was an excess of expansions in our male COS samples as compared to the controls, only 50% of the COS male samples had large RED products. Therefore, COS, like AOS, may well be multi-faceted in origin with multiple genetic loci contributing to the phenotype. Thus, expansions could be one of several genetic factors involved in the disorder. Alternatively, shorter expansions may be present in those samples with RED product sizes at or below the threshold of detection for the RED method (ie 120 nts). These 'undetectable' expansions may also be disease-related. In order to determine this, a locus-specific approach must be used when the genetic location of the TRE becomes known.
The RED method is a powerful technique for detecting trinucleotide repeat expansions; however, the detection is not gene-specific and also includes the detection of expansions not associated with a known phenotype. The expanded alleles seen in our male patients could thus arise from expansions in several loci of the genome. Recently, the chromosome 18 locus described here (CTG18.1) was identified. 40 This locus seems to account for a large fraction of the expansions found in healthy individuals as well as in some individuals with schizophrenia and bipolar disorder. As the role of CTG18.1 is currently unclear, we analyzed the material (COS and MDI) both with and without samples with CTG18.1 expansions. Even with the exclusion of samples with CTG18.1 expansions, there was a significant association of CAG/CTG expansions with COS but not with MDI. Statistical analysis of CTG18.1 expansions as a causal mechanism for COS and MDI indicates that expanded alleles have a weak but significant association to the pooled male patient group. In addition, individuals could harbor a second RED product in the same size range which would be obscured by the RED product arising from the CTG18.1 expanded allele. The excess of expansions in the male COS population as compared to controls, even with the exclusion of possible expansions at CTG18.1, suggests that more than one TRE may be involved in the etiology of COS.
Recent reports have suggested that the lack of ethnically matched populations in the control and patient samples could result in an inaccurate assessment of the contribution of a TRE to a disorder due to the varying frequencies of long repeats within different ethnic groups. 28, 37 Our samples were limited in size due to very demanding phenotyping and were therefore not well-matched ethnically. Consequently, subpopulations of these groups have been examined statistically to confirm the association of TREs with COS.
In conclusion, we have found a significant association between trinucleotide repeat expansions and childhood-onset schizophrenia. This supports previous findings which identified an association between TREs and AOS. The association between TREs and COS is specifically significant in the male population. It is therefore probable that the occurrence of an expanded trinucleotide repeat contributes to the genetic risk of COS, possibly in combination with other factors.
